Search across episodes, people, companies, and topics — or ask the AI agent for deeper research and structured analysis.

Browse all available podcasts, episodes, and categories. Explore Technology shows and discover new content to follow.

Manage your subscribed podcasts. New episodes are automatically analyzed with AI when published, so you never miss important discussions.

Your AI analysis feed. Every episode you analyze appears here with key insights, summaries, and extracted intelligence.

Browse individuals mentioned across analyzed episodes. See who's being discussed, in what context, and how often.

Track companies and organizations referenced in podcast discussions. Monitor brand mentions and competitive intelligence.

Explore recurring topics and themes extracted from analyzed episodes. Discover what subjects are driving podcast conversations.

Spot emerging trends identified by AI across analyzed episodes. See what's gaining momentum in podcast discussions.

Browse brands and advertisers identified across analyzed episodes. See which companies sponsor which shows and how often.

Rigel Pharmaceuticals

Mentioned in 3 analyzed podcast episodes across 2 shows

Mentioned On

Pharmaceutical Executive Pharma and BioTech Daily

Episode Mentions

Pharmaceutical Executive

Pharmaceutical Executive · May 13, 2026

Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu

“Entered exclusive global licensing agreement with Arvinas and Pfizer for Vepanu, a PROTAC cancer therapy”

PROTAC Technology and Protein DegradationCancer Therapy InnovationGLP-1 Receptor Agonist Therapies

Pharma and BioTech Daily

Pharma and BioTech Daily · May 13, 2026

Pfizer's $85M Breast Cancer Deal & FDA Shakeup | Pharma and Biotech Daily

“Partner in $85M Pfizer deal for targeted breast cancer therapy Vepanu with potential $320M in milestone payments”

FDA Leadership Transition and Regulatory StrategyPrecision Oncology and Targeted Breast Cancer TherapiesBiosimilar Competition and Market Erosion

Pharma and BioTech Daily

Pharma and BioTech Daily · Apr 23, 2026

Amneal's $1.1B Biosimilars Move & Merck's HIV Pill | Pharma and Biotech Daily

“Partnership with Eli Lilly ended as company exited RIPK1 inhibitor development for CNS disorders”

Biosimilars Market ExpansionAI Integration in Drug DiscoveryCAR-T Therapies for Autoimmune Diseases